Asia FX muted, dollar fragile as CPI data boosts Sept rate cut bets
In a recent transaction, Jack Anders, the Chief Financial Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), sold 1,864 shares of the company’s common stock. The shares were sold at an average price of $39.0403 per share, totaling approximately $72,771. The transaction occurred near the current trading price of $38.75, with the stock currently trading close to its InvestingPro Fair Value. Following this transaction, Anders retains ownership of 115,006 shares, which includes 60,150 restricted stock units. This sale was conducted under a pre-established Rule 10b5-1 plan, set up to cover tax obligations related to the vesting of restricted stock units. The company, valued at $7.09 billion, maintains a strong liquidity position with a current ratio of 14.2 and more cash than debt on its balance sheet. InvestingPro analysis reveals 7 additional key insights about RVMD’s financial health and future prospects, available in the comprehensive Pro Research Report.
In other recent news, Revolution Medicines has reported a net loss of $194.6 million for the fourth quarter of 2024, an increase from the $161.5 million loss in the same period of 2023. Despite the larger loss, the company maintains a strong cash position of $2.3 billion, supported by $823 million from an equity offering. Analysts from H.C. Wainwright have adjusted their price target for Revolution Medicines to $73, maintaining a Buy rating, while Needham has reduced its target to $59, also keeping a Buy rating. The company has announced plans for two additional registrational trials for its drug daraxonrasib, targeting pancreatic ductal adenocarcinoma, set to begin in the second half of 2025. Revolution Medicines projects a GAAP net loss between $840 million and $900 million for 2025, driven by increased expenses related to clinical development programs and commercial preparation efforts. Investors are advised to watch for forthcoming clinical data on zoldonrasib as a monotherapy and in combination therapy expected in 2025. Revolution Medicines is recognized as one of the most well-funded development-stage companies in precision oncology, with a strategic focus on advancing its portfolio of RAS inhibitors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.